Basic and Diluted Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2025

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net (Loss) Income Per Share

The following table sets forth the computation of basic and diluted net loss per share:

(In thousands, except for share and per share amounts)	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Numerator:
Net loss attributable to common stockholders—Basic	$	(16,382)	$	(36,763)	$	(55,570)	$	(70,175)
Net loss attributable to common stockholders—Diluted	$	(16,382)	$	(36,763)	$	(55,570)	$	(70,175)
Denominator:
Weighted-average common shares outstanding—Basic (1)	149,340,474		143,387,618		147,399,111		142,720,941
Weighted-average common shares outstanding—Diluted (1)	149,340,474		143,387,618		147,399,111		142,720,941
Net loss per share—Basic	$	(0.11)	$	(0.26)	$	(0.38)	$	(0.49)
Net loss per share—Diluted	$	(0.11)	$	(0.26)	$	(0.38)	$	(0.49)

(1)Excludes weighted-average Sponsor Vesting Shares subject to return of 1,500,000 and 2,472,527 shares for each of the three and nine months ended September 30, 2025 and 3,000,000 and 3,974,453 shares for the three and nine months ended September 30, 2024.

Schedule of Potentially Dilutive Securities for Common Stock

The following potentially dilutive securities for common stock were outstanding and excluded from diluted net loss per share as they are subject to performance or market conditions that were not achieved as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Options to purchase common stock	1,058,231	1,481,531	1,058,231	1,481,531
Performance-based stock awards	1,778,783	1,694,916	1,778,783	1,694,916
Earnout shares	25,000,000	25,000,000	25,000,000	25,000,000
Sponsor Vesting Shares	1,500,000	3,000,000	1,500,000	3,000,000

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Options to purchase common stock	1,396,566	2,873,258	1,396,566	2,873,258
Warrants to purchase common stock	35,476,627	35,476,627	35,476,627	35,476,627
RSU awards	13,240,133	10,473,845	13,240,133	10,473,845